62 related articles for article (PubMed ID: 11360194)
1. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
2. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Muraoka-Cook RS; Caskey LS; Sandahl MA; Hunter DM; Husted C; Strunk KE; Sartor CI; Rearick WA; McCall W; Sgagias MK; Cowan KH; Earp HS
Mol Cell Biol; 2006 Sep; 26(17):6412-24. PubMed ID: 16914727
[TBL] [Abstract][Full Text] [Related]
3. Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells.
Leung DW; Tompkins C; Brewer J; Ball A; Coon M; Morris V; Waggoner D; Singer JW
Mol Cancer; 2004 May; 3():15. PubMed ID: 15140260
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice.
Santore TA; Chen Y; Smit MJ; Iyengar R
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1671-6. PubMed ID: 11805301
[TBL] [Abstract][Full Text] [Related]
5. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells.
Wan J; Sazani P; Kole R
Int J Cancer; 2009 Feb; 124(4):772-7. PubMed ID: 19035464
[TBL] [Abstract][Full Text] [Related]
6. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
Pradeep CR; Zeisel A; Köstler WJ; Lauriola M; Jacob-Hirsch J; Haibe-Kains B; Amariglio N; Ben-Chetrit N; Emde A; Solomonov I; Neufeld G; Piccart M; Sagi I; Sotiriou C; Rechavi G; Domany E; Desmedt C; Yarden Y
Oncogene; 2012 Aug; 31(31):3569-83. PubMed ID: 22139081
[TBL] [Abstract][Full Text] [Related]
7. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.
Koletsa T; Kostopoulos I; Charalambous E; Christoforidou B; Nenopoulou E; Kotoula V
Neoplasia; 2008 Jul; 10(7):687-96. PubMed ID: 18592003
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
Taylor P; Gerder M; Moros Z; Feldmann M
Cancer Immunol Immunother; 1996 Mar; 42(3):179-84. PubMed ID: 8640846
[TBL] [Abstract][Full Text] [Related]
9. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator.
Asada S; Choi Y; Yamada M; Wang SC; Hung MC; Qin J; Uesugi M
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):12747-52. PubMed ID: 12242338
[TBL] [Abstract][Full Text] [Related]
10. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.
Zang ZJ; Ong CK; Cutcutache I; Yu W; Zhang SL; Huang D; Ler LD; Dykema K; Gan A; Tao J; Lim S; Liu Y; Futreal PA; Grabsch H; Furge KA; Goh LK; Rozen S; Teh BT; Tan P
Cancer Res; 2011 Jan; 71(1):29-39. PubMed ID: 21097718
[TBL] [Abstract][Full Text] [Related]
11. Role of exon-16-deleted HER2 in breast carcinomas.
Castiglioni F; Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
Endocr Relat Cancer; 2006 Mar; 13(1):221-32. PubMed ID: 16601290
[TBL] [Abstract][Full Text] [Related]
12. The role of alternative pre-mRNA splicing in cancer progression.
Choi S; Cho N; Kim EM; Kim KK
Cancer Cell Int; 2023 Oct; 23(1):249. PubMed ID: 37875914
[TBL] [Abstract][Full Text] [Related]
13. HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer.
Hart V; Silipo M; Satam S; Gautrey H; Kirby J; Tyson-Capper A
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2893-2912. PubMed ID: 34136934
[TBL] [Abstract][Full Text] [Related]
14. Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data.
Du JX; Liu YL; Zhu GQ; Luo YH; Chen C; Cai CZ; Zhang SJ; Wang B; Cai JL; Zhou J; Fan J; Dai Z; Zhu W
Ann Transl Med; 2021 Jan; 9(1):58. PubMed ID: 33553351
[TBL] [Abstract][Full Text] [Related]
15. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Hart V; Gautrey H; Kirby J; Tyson-Capper A
Oncotarget; 2020 Nov; 11(46):4338-4357. PubMed ID: 33245725
[TBL] [Abstract][Full Text] [Related]
16. Emerging Roles of SRSF3 as a Therapeutic Target for Cancer.
Zhou Z; Gong Q; Lin Z; Wang Y; Li M; Wang L; Ding H; Li P
Front Oncol; 2020; 10():577636. PubMed ID: 33072610
[TBL] [Abstract][Full Text] [Related]
17. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.
Gautrey H; Jackson C; Dittrich AL; Browell D; Lennard T; Tyson-Capper A
RNA Biol; 2015; 12(10):1139-51. PubMed ID: 26367347
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analysis of alternative transcripts in human breast cancer.
Wen J; Toomer KH; Chen Z; Cai X
Breast Cancer Res Treat; 2015 Jun; 151(2):295-307. PubMed ID: 25913416
[TBL] [Abstract][Full Text] [Related]
19. The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
Dittrich A; Gautrey H; Browell D; Tyson-Capper A
J Mammary Gland Biol Neoplasia; 2014 Dec; 19(3-4):253-70. PubMed ID: 25544707
[TBL] [Abstract][Full Text] [Related]
20. Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.
Lam L; Czerniecki BJ; Fitzpatrick E; Xu S; Schuchter L; Xu X; Zhang H
J Mol Biomark Diagn; 2014 Nov; 4(3):151. PubMed ID: 25089226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
